pressure biosciences inc.
14 norfolk avenue
south easton, ma 02375
(t) 508-230-1828
(f) 508-230-1829
info@pressurebiosciences.com

stock overview
symbol: pbio
exchange: otcqb
shares os1: 2.7m (12m fd)
float: -2.0m
revenue (fy2018): $2.46m
recent close: $2.40 (as of 1/28/20)
52-week range: $0.60 - $4.03
market capitalization2: $6.5m ($29m fd)
fiscal year end: december 31
transfer agent: computershare

company overview
pressure biosciences, inc. (otcqb: pbio) is a leader in the development & sale of innovative, enabling, pressure-based platform solutions for the worldwide life sciences industry. our products/services are based on three patented, pressure-enhanced platforms: (i) pressure cycling technology (“pct”), (ii) barofold technology (“barofold”), and (iii) ultra shear technology (“ust”).

the pct platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., critical steps performed by hundreds of thousands of scientists worldwide, such as cell lysis and biomolecule extraction). our primary focus is in making our recently released, gmp-compliant, next generation pct-based barocycler extreme instrument available globally to biopharmaceutical drug manufacturers for use in the design, development, characterization and quality control of biotherapeutic drugs. the pct platform is also used in such areas as biomarker and target discovery, soil & plant biology, anti-bioterror, and forensics. we currently have over 300 pct instrument systems placed in approximately 200 academic, government, pharmaceutical, and biotech research laboratories worldwide. there are over 120 independent publications highlighting the advantages of using the pct platform in scientific research studies, many from worldwide key opinion leaders. the pct platform is offered through the company’s research products & services group.

the barofold platform can be used to significantly impact and improve the quality of protein therapeutics. it employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. the barofold platform has been shown to remove protein aggregates in biotherapeutic drug manufacturing, thereby improving product efficacy and safety for both new-drug entities and biosimilar products. the barofold platform can help companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics. it is scalable and practical for standard manufacturing processes. this unique technology platform can help protein-based biopharmaceutical companies create and manufacture high quality, novel protein therapeutics and lower the cost of existing formulations. research and manufacturing licenses are available.

the ust platform is based on the use of intense shear forces from ultra-high pressure (greater than 20,000 psi) valve discharge. ust has been shown to turn hydrophobic extracts into stable, water-soluble formulations on a small, laboratory scale. the ust platform offers the potential to produce stable nanoemulsions of oil-like products in water. such formulations could potentially have enormous success in many markets, including inks, paints, and cosmetics, as well as in pharmaceuticals and nutraceuticals, such as medically important plant oil extracts, i.e., making cbd-enriched plant oil water soluble. we believe that ust has the potential to play a significant role in a number of commercially important areas, including (i) the creation of stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water), and (ii) the preparation of higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies, e.g., dairy products. the ust platform is currently being developed for commercialization.

1. shares outstanding (as of september 30, 2019) – includes approximately 2.7m common shares and 9.3m common share equivalents from preferred stock series d.
2. fully diluted market capitalization is calculated using common stock os and common equivalent shares os on a fully diluted basis.
INVESTMENT HIGHLIGHTS

- Seasoned Management Team & Board of Directors
- Three Novel, Enabling, Patent Protected & Proprietary Pressure-based Platforms
- Proven Core Technology with Multiple Applications (Over 300 PCT Systems Installed Globally)
- Sales into the Research Market (fast market penetration with minimal approvals required)
- Increasing Number of 3rd Party Publications from Marquee Laboratories
- PCT Breaks Through Bottlenecks to Enable and Accelerate Scientific Discovery & QC in Drug Development
- BaroFold Technology Impacts/Improves Protein Drug Therapeutics through Disaggregation and Refolding
- UST Produces Highly Stable Nanoemulsions for Many Applications, Including CBD, Cosmetics, and Food
- Significant Worldwide Market Opportunities: PCT (BioPharma $526B); BaroFold (Drug Processing $44B); UST (CBD $44B; Cosmetics $805B; BioPharma Drug Delivery $900B; Food and Beverages $5.65T)

RECENT & KEY ANNOUNCEMENTS

- **January 24, 2020:** PBI announced significant new order and near sellout on revolutionary nanoemulsification system for water-soluble CBD oil. Company said that additional orders are expected shortly.
- January 17, 2020: PBI reported the Company’s UST Platform was featured in a leading North American Cannabis Magazine and that the article highlighted the potential of the UST Platform to play a significant role in multiple billion-dollar markets, such as CBD, nutraceuticals, cosmetics, biopharmaceuticals, and food/beverage.
- January 9: PBI reported that the number of published scientific papers in 2019 citing the advantages of the Company’s PCT Platform remained strong, with over 20 journal articles for the second straight year
- December 19, 2019: PBI reported third quarter 2019 financial results, including record PCT consumables sales and strong revenue growth for scientific services (comprised of the BaroFold and UST business units). The Company reiterated earlier guidance that 2020 total revenue would be more than double 2019 total revenue.
- October 4: Zacks Small Cap Research Initiated Coverage on PBI.
- October 1: PBI’s proprietary PCT Platform said to fill pivotal role for tumor analyses in novel workflow presented at leading global gynecological cancer meeting. Nationally acclaimed scientists said the analysis of cancer tissue proteins from their novel workflow could lead to improved clinical management of gynecologic cancers.
- September 26: PBI’s PCT Platform was featured in 10 separate presentations at a major international science conference in Australia, by scientists from 17 research institutions worldwide. The presentations highlighted novel applications for the PCT Platform in cancer research and diagnostics.
- September 17: Daniel J. Shea was named Chief Financial Officer of PBI. Mr. Shea has 30-years diverse experience in acquisitions, capital markets, SEC reporting, and leading financial organizations.
- September 10: PBI’s PCT platform was identified by two prestigious research centers as pivotal for cancer biomarker discovery and for potential clinical diagnostics in studies using preserved (i.e., formalin-fixed paraffin-embedded, or FFPE) cancer biopsy tissue samples.
- August 22: PBI announced the receipt of three purchase orders for its revolutionary BaroShear K45 processing system for manufacturing water-soluble CBD nanoemulsions.
- August 15: PBI reported second quarter 2019 financial results, including record consumables sales for the PCT business unit and strong revenue growth for both the BaroFold and UST business units. The Company also gave guidance that total revenue in 2020 would be more than double total revenue in 2019.
- July 24: PBI announced a second major contract utilizing its BaroFold Protein Refolding and Disaggregation Biopharma Services Business and gave guidance for a significant increase from these services.
- June 27: PBI enters the CBD market with the launch of a novel instrument system to revolutionize manufacturing of high quality, water-soluble CBD Oil.
- June 26: PBI achieved the first major milestone in the development of a potential breakthrough processing method for higher quality and safer food and beverages – with a focus on dairy products.
- June 19: PBI’s ultra-high pressure HUB platform proved highly effective in studies to develop improved methods for food safety, addressing the need to prevent serious food-borne diseases caused by *E. coli* and Listeria.
- June 12: PBI’s patented PCT Platform was prominently featured in a record 15 presentations at a major international science conference, with a common focus on the platform’s significant use in cancer research, protein function, molecular biology, and biomarker discovery.
- April 2: PBI released a short video on the ability of the Company’s proprietary UST platform to create water-soluble CBD oil that disperses instantly when infused into soft drinks, sports drinks, and beer.
- March 4: PBI announced a collaboration with the world renown Steinbeis Centre (Germany) to develop a revolutionary method based on optimizing disease-fighting antibodies. The method will combine PBI’s patented PCT platform with the Centre’s innovative PROTEX-MS platform.
- February 21: PBI released scientific analyses confirming important benefits from processing CBD Oil with PBI’s UST platform: analyses showed UST-prepared CBD Oil solutions met challenging nanoemulsion specifications and exhibited minimal loss during processing.
- **January 7, 2019:** PBI launched its unique biopharmaceuticals contract services business, offering improved manufacturing for protein therapeutic candidates (a $250B global market).

BOARD OF DIRECTORS

- Mr. Jeffrey N. Peterson, Chairman
- Dr. Mickey Urdea
- Mr. Kevin A. Pollack, Esq.
- Mr. Richard T. Schumacher
- Mr. Vito Mangiardi

1/26/2020